Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunotherapy

DOT cells for colorectal cancer immunotherapy

Nature Cancer volume 6, pages 913–915 (2025)Cite this article

Subjects

Delta One T (DOT) cells are primarily Vδ1+ γδ T cells with strong cytotoxic activity, now in clinical studies for the treatment of leukemias but not yet evaluated in solid cancers. Adoptive transfer of DOT cells combined with butyrate or checkpoint inhibitors is now shown to be an effective therapy for colorectal cancer in preclinical models.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Checkpoint receptors on DOT cells and effect of checkpoint blockade.

References

  1. World Health Organization. https://go.nature.com/3EarPTD (11 July 2023).

  2. Lin, K. X. et al. Cancer Immunol. Immunother. 72, 3875–3893 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hayday, A., Dechanet-Merville, J., Rossjohn, J. & Silva-Santos, B. Science 386, 6717 (2024).

    Article  Google Scholar 

  4. Mensurado, S., Blanco-Domínguez, R. & Silva-Santos, B. Nat. Rev. Clin. Oncol. 20, 178–191 (2023).

    Article  CAS  PubMed  Google Scholar 

  5. Hu, Y. et al. Signal Transduct. Target. Therapy 8, 434 (2023). (2023).

    Article  CAS  Google Scholar 

  6. Almeida, A. R. et al. Clin. Cancer Res. 22, 5795–5804 (2016).

    Article  CAS  PubMed  Google Scholar 

  7. Mensurado, S. et al. Blood 143, 1488–1495 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. de Vries, N. L. et al. Nature 613, 743–750 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Yu, L. et al. Int. J. Cancer 153, 1684–1697 (2023).

    Article  CAS  PubMed  Google Scholar 

  10. Blanco-Domínguez, R. et al. Nat. Cancer https://doi.org/10.1038/s43018-025-00948-9 (2025).

    Article  PubMed  Google Scholar 

  11. Meraviglia, S. et al. Oncoimmunology 6, e1347742 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Bhat, J. et al. Front. Immunol. 10, 569 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Herrmann, T. & Karunakaran, M. M. Eur. J. Immunol. 54, e2451068 (2024).

    Article  PubMed  Google Scholar 

  14. de Gassart, A. et al. Sci. Transl. Med. 13, 616 (2021).

    Article  Google Scholar 

  15. Xu, Y. et al. Cell. Mol. Immunol. 18, 427–439 (2021).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Immunology, University of Kiel, Kiel, Germany

    Dieter Kabelitz

  2. University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

    Dieter Kabelitz

  3. Next Generation Sequencing Core Facility, German Cancer Research Centre, Heidelberg, Germany

    Jaydeep Bhat

Authors
  1. Dieter Kabelitz
    View author publications

    Search author on:PubMed Google Scholar

  2. Jaydeep Bhat
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Dieter Kabelitz.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kabelitz, D., Bhat, J. DOT cells for colorectal cancer immunotherapy. Nat Cancer 6, 913–915 (2025). https://doi.org/10.1038/s43018-025-00965-8

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s43018-025-00965-8

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer